# Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)

> **NCT04355364** · PHASE3 · TERMINATED · sponsor: **Fondation Ophtalmologique Adolphe de Rothschild** · enrollment: 77 (actual)

## Conditions studied

- COVID-19
- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** Dornase Alfa Inhalation Solution [Pulmozyme]
- **PROCEDURE:** standard procedure

## Key facts

- **NCT ID:** NCT04355364
- **Lead sponsor:** Fondation Ophtalmologique Adolphe de Rothschild
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-21
- **Primary completion:** 2021-12-20
- **Final completion:** 2021-12-20
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** No signal of benefit of treatment.
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04355364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04355364, "Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04355364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*